Selected Issues Concerning the Ethical Use of Big Data Health Analytics

I. Introduction

a. Big Data Generally

The terms Big Data and Big Data analytics originally derive from the terms artificial intelligence, business intelligence, and business analytics; terms used in the 1950s, 1990s, and 2000s, respectively. Although some argue that Big Data is an ambiguous term used for many concepts, most definitions share a common theme, succinctly summarized as, “large pools of data that can be captured, communicated, aggregated, stored, and analyzed.” Other definitions describe Big Data using 4 or even 5 Vs. (1) Volume - some data sets are measured in exabytes per day, (2) Velocity - data are collected in near real-time, (3) Variety – data may be images, video, text, meta-data, audio, location information, etc. (4) Veracity - data are unpredictable and difficult to de-identify, and (5) Variability – data come in peaks and valleys. Smart algorithms can identify and predict behavior of target groups and give insight into real-time events. This permits decision makers to rely on evidence using Big Data instead of having to rely on intuition. However, besides the benefits of Big Data, simultaneously a growing concern about use of (personal) data arises. Internet users are increasingly being monitored without giving personal data, through the use of digital cookies, electronic identifiers left on their browsers, or through their Internet Protocol (IP) addresses, according to a European Union commissioned report. Monitoring is not limited to the Internet however. Mobile phones, cameras, payments, store loyalty cards, biometrics, interactive services, and social media networks can all be used to capture data and monitor users. Despite these serious concerns, common reason suggests that the benefits of big data, including those to manufacturing, healthcare treatment and research, communications, and transportation currently outweigh the drawbacks.

---

4 Andrew McAfee and Erik Brynjolfsson, Big Data: The Management Revolution Exploiting vast new flows of information can radically improve your company’s performance - But first you’ll have to change your decision-making culture, 1-19, Harvard Business Review, (Oct 2012).
5 Id.
b. Special considerations of Health Big Data

Privacy advocates have spent the better part of a decade teaching people that their data is precious and that once it’s online, it’s online forever. As this message finally takes hold, and users have finally started to limit the data they share online, Big Data initiatives are asking users to freely give up their data with no direct or immediate benefit. Without transparency of Big Data practices, users may continue reducing the data they share, especially health data, because they don’t understand the collective value of their data. It is in this environment that the review boards of today and tomorrow must operate.

Traditionally, internationally accepted frameworks have guided decision makers and health professionals to decide what they should and should not do when dealing with health data. This was necessary because health data has customarily warranted special protections. However, in the era of rapid technology advancement, previously accepted frameworks are no longer sufficient for three reasons. First, innovation is outpacing the frameworks themselves, many of which reflect the world of data collection decades ago. Second, health data is increasingly being collected outside of traditional healthcare settings. Third, data are then shared with third parties not only for research, but also for commercial gain.

The new environment in which health data are collected supplement traditionally crucial questions such as: ‘how to secure data and limit access?’ with new questions such as: ‘should a software developer be held criminally responsible if a flaw in their software permits a malicious individual to kill someone by tampering with a remotely accessible insulin pump?’ The insulin pump was connected to the Internet to permit remote control, but also so its data could be shared and analyzed as part of a Big Data initiative. The benefits to the diabetic patient, and others, are real, but are they worth putting people’s lives at

---

7 Nuremberg Code: http://www.hhs.gov/ohrp/archive/nurcode.html
The Belmont Report: http://www.hhs.gov/ohrp/archive/belmont.html
CIOMS/WHO International ethical guidelines from Biomedical Research involving Human Subjects: http://www.recerca.uab.es/ceeh/docs/CIOMS.pdf
Council of Europe’s Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the application of Biology and Medicine: http://www.coe.int/nl/web/conventions/full-list-/conventions/treaty/164
OECD Privacy principles: http://oecdprivacy.org/
risk? Big Data initiatives in other industries typically do not implicate life or death decisions with the frequency of health Big Data.

c. Big Data questions

Big data brings forth a multitude of proposed benefits, but each raises an equally powerful disincentive: (1) Big Data may lead to the creation of better tools, services, and public goods, but will it do so at the expense of privacy incursions and invasive marketing?; (2) Big Data may help us understand political movements and online communities, but will it also be used to track protesters and suppress freedom of speech?; (3) Big Data may positively transform how we study human communication and culture, but will it also narrow the range of research options and alter what ‘research’ means? Recent developments have raised new thought provoking questions and this paper aims to discuss two of these unique questions that apply to the healthcare industry specifically:

1. Is it ethical to control or influence user behavior through health Big Data?
2. Should potentially life-saving information be shared with a patient who has consented to sharing data for an unrelated purpose?

II. Ethics of Controlling User Behavior

a. What’s the risk?

Profiling and targeting of users through prescriptive analytics can start driving consumer behavior, rather than the other way around. This means that if a consumer acts upon a personalized offer, more refined personalized offers will follow, which in turn slowly blocks the consumer from making other choices because they are less aware of alternatives. Removing options from consumer consideration interferes with the principle of free choice. This practice may be interesting commercially, but ethically it is a slippery slope.

One example of how an awareness of data monitoring led to a change in user behavior occurred in the years following Edward Snowden’s leaks of National Security Agency (NSA) monitoring capabilities and activities. With knowledge that the NSA monitored user activity online, search terms for sensitive health keywords, such as ‘therapy,’ decreased. People’s personal space and right to control their own actions were violated. Further troubling is that the consequences of this violation extend beyond merely avoiding certain searches to people avoiding searching for help with their life-threatening mental illnesses, affecting them and the public.

---

10 Id.
From pedometers to light bulbs, the private sphere in which people are tracked and monitored is rapidly increasing. As the number and variety of Internet enabled devices increases, wherein even furniture can interact with people, a slew of new data is created just waiting to be mined or exploited.

Paranoia and conspiracy theories aside, there is a possibility that people will become risk-averse, and modify their behavior, as continuous monitoring leads to feelings of “creepiness.” Even if behaviors do not change, that may indicate a significant change in sociological norms, namely, a desensitization to being monitored.

Controlling user behavior comes in another less obvious form. A benefit of the big data trend for organizations and research institutions is that they may profit from the performance of medical and imaging procedures, either as it enables them to supply medical monitoring devices (for example, to monitor a patient’s vital signs after surgery) or to gain insight from the acquired data, which can have commercial value. They therefore have a financial incentive to perform procedures which may contribute to research, but which are not medically necessary for the patient. Researchers seeking to increase their data set, and institutions seeking to maximize profits, may consciously or subconsciously influence patient behavior. By definition, unnecessary medical procedures expose patients to the unnecessary risks of those procedures.

Using Big Data, not the needs of the patients themselves, as the driver to initiate medical treatment shocks the collective conscience of the medical field and shatters its foundations in the Hippocratic Oath. But what if the equation changes so that the patients provide informed consent (a subject to lengthy discussion on its own\textsuperscript{13}) to the potentially superfluous procedures and even receive payment in exchange for their participation?\textsuperscript{14} This gray area is the emerging domain of the ethics board.

b. The role of an ethics board

The Privacy and Ethics Review Board (PERB) has a responsibility to spot the issues raised above and should aim to identify and mitigate risks to consumer. Before the PERB can meet to achieve this lofty objective, its members must be chosen. Members can and should come from different backgrounds with different motivational interests, but this means their selection and balance is particularly

\begin{itemize}
\item \textsuperscript{11} Mike Gualtieri, Digital Creepiness: How Not To Spook Your Customers, Forrester, 1-10, (Jul 2014). Defining creepiness as: “A feeling by a customer that a digital experience offered by a company knows more about them than they should and is using that information in a way that makes the customer feel uncomfortable”
\item \textsuperscript{14} Hugo Greenhalgh, Sell your own personal data, Financial Times, (Oct 2015). http://www.ft.com/cms/s/0/8e51ecd4-7327-11e5-bdb1-e6e4767162cc.html (subscription required).
\end{itemize}
important. A Big Data code of ethics stating the values an organization commits to upholding, unites the employees, contractors, and PERB members and fosters a more consistent and fair PERB. While involving privacy and ethics specialists is an obvious start, involving the primary groups likely to be affected by the choices being made, such as the consumers from whom data is collected and industry professionals, is also advised. Consumers should be empowered with the ability to review data collected about them, have an ability to withdraw it at any time, and to receive a clear benefit from sharing their data. In the scenario of unnecessary medical procedures, the threshold for informed consent should be raised and counsel should also be consulted.

III. Communicating Unexpected Findings to Data Subjects

The second ethical question this paper explores is whether to communicate unexpected findings to data subjects. For example, when analysis on fetal stem cells in prenatal testing reveals that the mother has cancer, should she be informed of her condition? Should the answer depend on the religion or ethnicity of the patient? Consider that in Judaism, one is obligated to share medical information that may save a life, but in China, the cultural norm is not to inform an ill patient of bad news because they are thought of as a child that needs to be protected by avoiding upsetting news.

Even if a principal investigator wants to inform a data subject about the presence of disease, this might be difficult to do if their data has been de-identified in an effort to protect them. This creates a counterintuitive incentive to either not de-identify data, or to separately store data that would permit re-identification. Some may argue that the risk of loss of privacy for everyone in a study is worth the potential benefit of a subgroup of members. Unfortunately, this position may discourage participation and decrease the value of a study. These trade-offs need to be considered and acted upon accordingly.

One compromise to the scenario presented above would be to provide participants with a choice to opt-in to receiving incidental findings. This permits participants to retain control over their data without impacting the security of every participant’s data and permits religious and ethnic preferences to be taken into account. It also avoids having to rely on a PERB to make this decision on behalf of participants. Another option to minimize risk is to have a third party store the re-identification information.

IV. How do other industries handle similar ethical issues?

Ethical conundrums are not unique to the healthcare industry and so one source of valuable guidance is to explore what other industries are doing in the face of similar challenges. For years, people have been asking, “should an autonomous car seeking to avoid a collision swerve and hit a person or maintain course and risk serious injury to the driver?” What if swerving would hit multiple people and the driver

---

is alone? In the case of autonomous cars these choices are programmed at the factory, in a vacuum, devoid of unique circumstantial inputs.¹⁷

Pilot programs are bridging the gap between the automotive and health industries through car seats with health sensors that can be used to detect when the driver has a heart attack or is falling asleep. The benefits of a car that can drive its occupant to the hospital are indisputable, but raise the question whether these benefits outweigh the ethical and privacy risks concerning misused data.

There will never be universal agreement with the programmatic choices built into our cars, but developing and utilizing “ethics by design” principles (in the same vein as “privacy by design”¹⁸ principles) will at least make the decisions more understandable, if not more fair. Supporters of this further argue that ethical considerations should not be the exclusive domain of ethicists, but rather should be incorporated at every phase and in every aspect of design.¹⁹ Others advocate for the inclusion of philosophers to assist with the ethical investigations.²⁰ Health Big Data practitioners must be equally forward thinking or risk potential government regulation if their PERBs are ineffective.

V. Conclusion and What’s Next?

a. What are the issues we haven’t thought about yet?

With the onslaught of Internet enabled devices in the past few years, new questions about how to protect consumer privacy and how to ethically use data have arisen frequently. This rapid evolution requires constant innovation in how PERBs operate. Checklists and questionnaires are no longer sufficient to identify the majority of risks and concerns. PERBs must be prepared to innovate as quickly as the industries they seek to examine.

b. How will Privacy and Ethics Review Boards need to evolve?

Responsible data stewardship and effective management of ethical and legal risks for Big Data initiatives can only be achieved with a well-designed PERB that operates nimbly and transparently. It must morally assess new data initiatives by providing a predictive and all-encompassing framework of how various involved stakeholder groups may respond and the possible moral and ethical challenges which need to be overcome. The structure and composition of this board is the first step toward engaging stakeholders

¹⁸ “Privacy by design” refers to the principle of building in privacy features or decisions into early stages of design, to avoid time consuming fixes afterwards when violations occur.
²⁰ See Knight, supra note 17
and fostering independence. The guidelines for the similarly-purposed Institutional Review Board (IRB)\textsuperscript{21} are a good start, but without modification may fail in this new arena. A standard IRB consisting of at least five individuals, contains: (1) at least one scientific member (2) at least one non-scientific member, and (3) at least one member not affiliated with the organization. An ideal PERB builds on this model by including underrepresented groups needed for an independent and effective judgement.

The PERB should be a stable internal body containing external stakeholders involved on an as-needed basis. This is necessary to establish that affected parties are sufficiently represented and to establish that appropriate specialists are consulted for previously un-thought of issues. The PERB should therefore include: (a) at least one lawyer (internal/external), (b) at least one business representative (internal), (c) at least one representative of a key stakeholder group in order to safeguard their engagement and provide feedback in the moral deliberation process (external), (d) one Secretary to moderate a structured conversation (internal), and (e) an open seat, called “markets” in which market or country representatives sit, in order to map out cultural or national differences in moral judgments and ways to reach consensus (internal/external).

c. Final thoughts

Big Data promises abundant opportunities for added value. The potential annual value of Big Data to Europe’s public sector administration was calculated to be €250 billion.\textsuperscript{22} Using Big Data, managers successfully rely on evidence rather than intuition permitting companies to predict consumer behavior and health risks in ways previously thought impossible.\textsuperscript{23} However, besides the undisputable benefits of Big Data, there is a simultaneously growing concern over the use of personal data, and especially personal health data.

As the examples above and elsewhere illustrate, the risks of Big Data extend beyond feelings of creepiness, to life and death situations. Whereas creepiness may be overcome by both educating and engaging data subjects into moral data decisions, giving data owners back some degree of control (“Data doesn’t invade people’s lives. Lack of control over how it’s used does.”\textsuperscript{24}), some larger challenges need deeper consideration and discourse.

The future of ethical use of our data depends on an evolution from IRBs to PERBs containing a wider variety of interested stakeholders and specialties. This paper is a starting point to facilitate internal discussions regarding the structure, purpose, and challenges of a PERB. Success will depend on the engagement of affected stakeholders and the respect and weight given to their opinions.\textsuperscript{25} Continuous

\textsuperscript{22} See Manyika, supra note 3.
\textsuperscript{23} See McAfee, supra note 4.
\textsuperscript{24} Alistar, Big Data is our generation’s civil rights issue, and we don’t know it, posted in Perambulation in Solve for interesting. Otherwise life is dull, (2012). http://solveforinteresting.com/big-data-is-our-generations-civil-rights-issue-and-we-dont-know-it/

Copyright © 2015 Deloitte Development LLC. All rights reserved.
attention to ethical concerns by everyone involved, not just the PERB, will strengthen the image of health Big Data and help to support realizing its full value.

Written by Lieke Jetten and Stephen Sharon

For questions, please contact:

**Lieke Jetten**

Privacy Advisor | Privacy Team | Deloitte Risk Services B.V. | Cyber and Privacy Advisory

Deloitte Netherlands
Gustav Mahlerlaan 2970, 1081 LA Amsterdam, The Netherlands
P.O. Box 175, 1180 AD Amstelveen, The Netherlands
Tel/Direct: +31 (0)88 288 42 43 | Mobile: +31 (0)6 10 37 13 59
ljetten@deloitte.nl | www.prepareforprivacy.nl | https://nl.linkedin.com/in/liekejetten | www.deloitte.com

**Stephen Sharon, JD, CIPP/US**

Senior Consultant | Deloitte Advisory | Cyber Risk Services
Deloitte & Touche LLP
100 Kimball Drive, Parsippany, NJ 07054
Tel/Direct: +1 973 602 4449 | Fax: +1 877 470 3301 | Mobile: +1 201 310 9144
STSharon@deloitte.com | www.deloitte.com

This article contains general information only and Deloitte is not, by means of this article, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This article is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor.

Deloitte shall not be responsible for any loss sustained by any person who relies on this article.

**About Deloitte**

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. Please see www.deloitte.com/about for a detailed description of DTTL and its member firms. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.